Anixa Biosciences (NASDAQ:ANIX) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $7.00 target price on the stock.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $3.05 on Wednesday. The firm’s fifty day moving average price is $2.59 and its 200 day moving average price is $3.27. The company has a market capitalization of $97.63 million, a price-to-earnings ratio of -8.24 and a beta of 0.89. Anixa Biosciences has a 12 month low of $2.14 and a 12 month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Tuesday, June 4th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. As a group, sell-side analysts forecast that Anixa Biosciences will post -0.43 earnings per share for the current year.

Insider Buying and Selling

In other Anixa Biosciences news, CEO Amit Kumar purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was purchased at an average price of $2.41 per share, for a total transaction of $60,250.00. Following the purchase, the chief executive officer now directly owns 516,925 shares in the company, valued at $1,245,789.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Lewis H. Titterton, Jr. bought 10,738 shares of Anixa Biosciences stock in a transaction dated Friday, June 7th. The stock was bought at an average price of $2.52 per share, for a total transaction of $27,059.76. Following the purchase, the director now owns 848,775 shares of the company’s stock, valued at $2,138,913. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Amit Kumar bought 25,000 shares of Anixa Biosciences stock in a transaction dated Friday, June 7th. The stock was purchased at an average price of $2.41 per share, with a total value of $60,250.00. Following the purchase, the chief executive officer now directly owns 516,925 shares in the company, valued at approximately $1,245,789.25. The disclosure for this purchase can be found here. Insiders acquired a total of 47,723 shares of company stock worth $119,711 in the last 90 days. Company insiders own 22.60% of the company’s stock.

Institutional Trading of Anixa Biosciences

Several hedge funds have recently made changes to their positions in ANIX. International Assets Investment Management LLC lifted its stake in shares of Anixa Biosciences by 274.6% in the 4th quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock worth $2,110,000 after acquiring an additional 39,820 shares during the period. Simplicity Wealth LLC acquired a new stake in shares of Anixa Biosciences in the 1st quarter worth $44,000. Staley Capital Advisers Inc. acquired a new stake in shares of Anixa Biosciences in the 1st quarter worth $31,000. Finally, Virtu Financial LLC lifted its stake in shares of Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after purchasing an additional 5,183 shares during the period. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.